[1] Niilura K.Vacuolar ATPase as a drug discovery.Drug News Perspect.2006;19(3):139-144.
[2] 游海燕,邓云,覃文新.V-ATPases 的功能及其抑制剂研究进展[J].生命科学,2009,21(4): 499-504.
[3] 杜文喜,肖鲁伟,吴承亮,等.两种不同培养方法对破骨细胞ATPase a3基因表达和骨吸收活性的影响[J].浙江中医药大学学报,2009,33(1):29-31.
[4] 吴鹰,沈志强.破骨细胞空泡型质子泵及其抑制剂的研究进展[J].国外医学:药学分册,2005,32(3):188-191.
[5] Cipriano DJ,Wang Y,Bond S,et al.Structure and regulation of the vacuolar ATPase. Biochim Biophys Acta. 2008;1777(7-8): 599-604.
[6] 孟祥阁.破骨细胞分化的信号转导系统[J].科协论坛,2009,1: 75-76.
[7] Lacey DL,Timms E,Tan HL,et al.Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell.2008;93(2):165-176.
[8] 赵晴潇,何爱民.破骨细胞分化发育中的信号转导及转录因子研究进展[J].山东医药,2009, 49(19):111-113.
[9] 黄怡,李玉冲.破骨细胞功能与形成相关调节因子研究进展[J].国际骨科学杂志,2009,30(1):51-53.
[10] 陈建庭,张忠民,金大地,等.血小板衍生生长因子-AA对破骨细胞功能的影响[J].中华外科杂志,2010,38(6):465-467.
[11] Nordstron T,Shrode LD,Rotstein OD,et al.Chronic extracellular acidosis induces plasmalemmal vacuolar type H+ ATPase activity in osteoclasts.J Biol Chem.2007;272: 6354-6360.
[12] Beutler JA,McKee TC.Novel marine and microbial natural product inhibitors of vacuolar ATPase.Curr Med Chem. 2003; 10(9):787-796.
[13] Zhao Q,Shao J,Chen W,et al.Osteoclast differentiation and gene regulation.Front Biosci.2007;12:2519-2529
[14] 刘振东,马梦然.骨折愈合理论研究现状[J].中国矫形外科杂志, 2010,18(16):1402-1405.
[15] Li YP,Chen W,Liang Y,et al. Atp6i deficient mice exhibit severe osteopetrosis due to loss of osteoclast-me-diated extracellular acidification.Nat genet.2009; 23(4):447-451.
[16] Xu J,Cheng T,Feng HT,et al.Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.Histol Histopathol. 2007,22(4): 443-445.
[17] 吴承亮,李陶冶,吴俊生,等.右归饮对体外培养破骨细胞分化与功能的影响[J].中华中医药学刊,2010,28(2):304-307.
[18] Rousselle AV,Heymann D.Osteoclastic acidification pathways during bone resorption.Bone.2007;30:533-540.
[19] 高建军,王洪复.破骨细胞成熟和活化以及骨吸收机制[J].国外医学:内分泌学分册, 2007;18(2):57-61.
[20] Ryu J,Kim HJ,Chang EJ,et al.Kim Sphingosine 1-phosphate as a regulast differentiation and osteoclast-osteoblast coupling. EMBO J.2006;25(24):5840-5851.
[21] 苏佳灿,许硕贵,张春才.骨重建中细胞因子的作用及机制[J].中国矫形外科杂志,2008, 8(6):593-595.
[22] 狄升蒙,田宗成,高翔,等.破骨细胞研究进展[J].细胞生物学杂志, 2009,31(6):792-798.
[23] 扈英伟,于世凤.破骨细胞质子泵调控的研究进展[J].中国骨质疏松杂志,2010,7(1): 88-90.
[24] Schlesinger PH,Blair HC,Teitelbaum SL,et al.Characterization of the Osteoclast Ruffled Border Channel and Its Role in Bone Resorption.J Biol Chem.2007;272(6): 18636-18643.
[25] 刘继中,胡藴玉.破骨细胞骨吸收机制的研究进展[J].中国矫形外科杂志,2012,9(4): 401-402.
[26] 文剑明,郑铭豪.破骨细胞的形成、功能及细胞因子的调节[J].中国骨质疏松杂志,1998, 4(1):64-67.
[27] Manolson MF,Yu H,Chen W,en al.The a3 isoform of the 100kDa V-ATPase a3 subunit is highly but differentially expressed in large(≥10nuclei) and small (≤5nuclei) osteoclasts.J Biol Chen.2008;278(49):49271-49278.
[28] Ramanan R,Kannan K,Sivanesan SD,et al.Bio-sequestration of carbon dioxide using carbonic anhydrase enzyme purified from Citrobacter freundii.World J Microbiol Biotechnol. 2009; 25(6):981-987.
[29] Xu J,Feng HT,Wang C,et al.Effects of bafilomycin A1:aninhibitor of vacuolar H+-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts.J Cell Biochem.2003;88(6):1256-1264.
[30] Zhao C,Irie N,Takada Y,et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis.Cell Metabolism. 2006; 4(2):111-121.
[31] Matsumoto N, Daido S, Sun-Wada GH,et al.Diversity of proton pumps in osteoclasts: V-ATPase with a3 and d2 isoforms is a major form in osteoclasts.Biochim Biophys Acta. 2014;1837(6):744-749.
[32] Ochotny N, Voronov I, Owen C,et al.The R740S mutation in the V-ATPase a3 subunit results in osteoclast apoptosis and defective early-stage autophagy.J Cell Biochem. 2013;114 (12): 2823-2833.
[33] Crasto GJ, Kartner N, Yao Y, et al.Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity.J Cell Biochem. 2013;114(4):929-941.
[34] Voronov I, Ochotny N, Jaumouillé V, et al.The R740S mutation in the V-ATPase a3 subunit increases lysosomal pH, impairs NFATc1 translocation, and decreases in vitro osteoclastogenesis.J Bone Miner Res. 2013;28(1):108-118.
[35] Thudium CS, Jensen VK, Karsdal MA, et al.Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis. Curr Protein Pept Sci. 2012;13(2):141-151.
[36] Ochotny N, Flenniken AM, Owen C, et al.The V-ATPase a3 subunit mutation R740S is dominant negative and results in osteopetrosis in mice.J Bone Miner Res. 2011;26(7):1484- 1493.
[37] Nyman JK, Väänänen HK.A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.Calcif Tissue Int. 2010;87(3):273-283.
[38] Ochotny N, Van Vliet A, Chan N, et al.Effects of human a3 and a4 mutations that result in osteopetrosis and distal renal tubular acidosis on yeast V-ATPase expression and activity.J Biol Chem. 2006;281(36):26102-26111.
[39] Bhargava A, Voronov I, Wang Y,et al.Osteopetrosis mutation R444L causes endoplasmic reticulum retention and misprocessing of vacuolar H+-ATPase a3 subunit.J Biol Chem. 2012;287(32):26829-26839.
[40] Kartner N, Yao Y, Li K,et al.Inhibition of osteoclast bone resorption by disrupting vacuolar H+-ATPase a3-B2 subunit interaction.J Biol Chem. 2010;285(48):37476-37490.
[41] Serrano EM, Ricofort RD, Zuo J,et al.Regulation of vacuolar H(+)-ATPase in microglia by RANKL.Biochem Biophys Res Commun. 2009;389(1):193-197.
[42] Xu J, Cheng T, Feng HT,et al.Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.Histol Histopathol. 2007;22(4):443- 454. |